Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

181 through 190 of 232

Relevance: Medium-High

pointerRelevance

Quality of Writing: Medium

pointerQuality of Writing

Personal Story : Men get breast cancer too

Most relevant for: Men diagnosed with breast cancer

Cathy Free's piece for People, “Men Have Breasts Too: New York Man Who Survived Stage 2 Breast Cancer Spreads Message,” tells the stories of two men whose experiences with breast cancer inspired them to speak openly about breast cancer awareness for men. (11/29/16)

Read More
Men get breast cancer too

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Study : Cancer treatment costs can vary widely

Most relevant for: People diagnosed with breast cancer

Healthcare providers cannot give their breast cancer patients information on chemotherapy treatment costs because not enough is known about the exact costs. New research finds that costs vary not only between different cancer treatments, but also between similar treatments, such as all treatments that target HER2+ breast cancer. (11/22/16)

Read More
Cancer treatment costs can vary widely

Relevance: Medium

pointerRelevance

Quality of Writing: Medium-Low

pointerQuality of Writing

Personal Story : Why one woman passed on genetic testing

Most relevant for: People considering genetic testing and people who are Ashkenazi Jewish

What are reasons to get or not get genetic testing? Cynthia Graber gives her thoughts on the matter in her Wired opinion piece, "Why I Won't Get the Genetic Test for Breast Cancer." (11/15/16)

Read More
Why one woman passed on genetic testing

Relevance: Medium-High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing

Personal Story : CBS News brings attention to the issues facing young metastatic breast cancer patients

Most relevant for: Women diagnosed with metastatic breast cancer

Beth Caldwell is a former civil rights lawyer, a mother of two, and a wife who was diagnosed with stage 4 metastatic breast cancer when she 37. Mary Brophy Marcus covered Beth’s story in her piece, “The hardest part” of breast cancer under 40, for CBS News. (11/8/16)

Read More
CBS News brings attention to the issues facing young metastatic breast cancer patients

Relevance: Medium

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women

Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries

Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)

Read More
Removing ovaries before age 50 may increase the risk of chronic conditions for some women

Relevance: Medium

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Study : Breast cancer mortality among Hispanic women in the United States varies by country of origin

Most relevant for:

"Hispanic" is a broad ethnic category that includes people from numerous countries. When discussing breast cancer statistics, Mexicans, Cubans, Puerto Ricans and people whose families originated in Central and South America are typically grouped into one Hispanic category. A new study looked at whether the country of origin affected breast cancer prevalence and mortality rates in Hispanic women in the U.S. (10/25/16)

Este artículo está disponible en español.

Read More
Breast cancer mortality among Hispanic women in the United States varies by country of origin

Relevance: Medium

pointerRelevance

Strength of Science: Medium

pointerStrength of Science
View Related Clinical Trials

Study : Breast cancer screening should be tailored to a woman’s risk factors and breast density

Most relevant for: Women who are at high risk for breast cancer due to family history, dense breasts, LCIS, or multiple biopsies

The United States Preventative Services Task Force (USPSTF) recommends a screening mammogram every other year for women ages 50-74 who are at average risk for breast cancer. But do all patients in this category benefit from this screening regimen? 10/18/16

Read More
Breast cancer screening should be tailored to a woman’s risk factors and breast density

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing

Article : Huffington Post article brings attention to metastatic breast cancer

Most relevant for: People diagnosed with metastatic breast cancer

Barbara Jacoby's Huffington Post piece, "How do breast cancer and metastatic breast cancer differ?" emphasizes the need for more treatment options for patients with advanced breast cancer.

Read More
Huffington Post article brings attention to metastatic breast cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline

Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Read More
Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Relevance: Medium

pointerRelevance

Quality of Writing: High

pointerQuality of Writing

Article : A cancer patient’s tumor is genetically profiled—how does that info help treatment?

Most relevant for: People diagnosed with advanced cancer

Jessica Wapner's Scientific American article explores the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians. (9/20/16). Update: THIS INFORMATION HAS BEEN UPDATED. In late 2017, the FDA approved two separate tumor profiling tests to help guide treatment choices. The FoundationOne CDx (F1CDx) genomic test has been approved to test for 15 different targeted therapies used to treat five types of cancer, including ovarian, colorectal, lung, breast and melanoma. The FDA also approved the MSK-IMPACT and developed for use by Memorial Sloan Kettering Cancer Center (MSKCC) to scan tumor samples for 468 different cancer-associated mutations or alterations.

Read More
A cancer patient’s tumor is genetically profiled—how does that info help treatment?